NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $39.36 -0.56 (-1.40%) Closing price 04:00 PM EasternExtended Trading$39.35 -0.01 (-0.01%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Harmony Biosciences Stock (NASDAQ:HRMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$38.91▼$40.3550-Day Range$35.24▼$42.8652-Week Range$25.52▼$43.49Volume507,272 shsAverage Volume867,210 shsMarket Capitalization$2.29 billionP/E Ratio12.78Dividend YieldN/APrice Target$47.44Consensus RatingHold Company Overview Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and marketing therapies for patients with rare neurological disorders. The company’s activities center on conditions that are often underserved by conventional treatment options, including sleep disorders and other central nervous system diseases. Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled medication that acts as a histamine-3 receptor antagonist/inverse agonist. In the United States, WAKIX is approved to treat excessive daytime sleepiness or cataplexy in adults with narcolepsy and is also approved for certain pediatric patients with narcolepsy. The company continues to evaluate additional applications and investigational therapies addressing neurological conditions. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences primarily serves the U.S. market through its commercial and medical operations. The company is led by Jeffrey M. Dayno, M.D., who serves as president and chief executive officer and has experience in neurology, sleep medicine and pharmaceutical development.AI Generated. May Contain Errors. Read More Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 97% of companies evaluated by MarketBeat, and ranked 12th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingHarmony Biosciences has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialHarmony Biosciences has a consensus price target of $47.44, representing about 20.5% upside from its current price of $39.36.Amount of Analyst CoverageHarmony Biosciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth7.12% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 7.12% in the coming year, from $3.79 to $4.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 12.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 12.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.96.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.31. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.93% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 4.34.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 10.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.88 News SentimentHarmony Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search Interest9 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows7 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,108,520.00 in company stock.Percentage Held by Insiders11.00% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRMY Stock News HeadlinesHarmony Biosciences Holdings, Inc. Announces Poster Presentation Featuring Information From Ongoing Phase 3 Trials Of HBS-301October 3 at 2:25 PM | marketscreener.comMDeutsche Bank Lifts Price Target on Harmony Biosciences Holdings to $42 From $39, Keeps Hold RatingOctober 1, 2026 | marketscreener.comMMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.October 6 at 1:00 AM | Paradigm Press (Ad)Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy DaysOctober 1, 2026 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)September 26, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)September 26, 2026 | theglobeandmail.comHarmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in StockSeptember 19, 2026 | insidertrades.comHarmony Biosciences (NASDAQ:HRMY) Insider Kumar Budur Sells 5,500 Shares of StockSeptember 10, 2026 | insidertrades.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $37.42 at the start of the year. Since then, HRMY stock has increased by 5.2% and is now trading at $39.36. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its quarterly earnings data on Tuesday, August, 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.32. Harmony Biosciences's quarterly revenue was up 30.3% on a year-over-year basis. Read the conference call transcript. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $115 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 5,348,837 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional shareholders include CX Institutional (0.37%) and Argent Capital Management LLC (0.03%). Insiders that own company stock include Sandip Kapadia, Kumar Budur, Jeffrey Dierks and Jeffrey M Dayno. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today10/06/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HRMY's financial health is in the Green zone, according to TradeSmith. HRMY has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees293Year Founded2017Price Target and Rating Average Price Target for Harmony Biosciences$47.44 High Price Target$70.00 Low Price Target$28.00 Potential Upside/Downside+20.5%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$3.08 Trailing P/E Ratio12.78 Forward P/E Ratio10.39 P/E Growth0.31Net Income$158.69 million Net Margins18.88% Pretax Margin25.13% Return on Equity20.06% Return on Assets14.15% Debt Debt-to-Equity Ratio0.13 Current Ratio3.48 Quick Ratio3.45 Sales & Book Value Annual Sales$959.90 million Price / Sales2.39 Cash Flow$3.16 per share Price / Cash Flow12.47 Book Value$15.11 per share Price / Book2.60Miscellaneous Outstanding Shares58,236,000Free Float51,830,000Market Cap$2.29 billion OptionableOptionable Beta1.01 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:HRMY) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
